

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0231

TITLE: Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer

PRINCIPAL INVESTIGATOR: Mitchell H. Sokoloff, M.D.

CONTRACTING ORGANIZATION: The University of Chicago  
Chicago, Illinois 60637

REPORT DATE: August 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040112 130

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> August 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Aug 2002 - 31 Jul 2003)	
<b>4. TITLE AND SUBTITLE</b> Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0231	
<b>6. AUTHOR(S)</b> Mitchell H. Sokoloff, M.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> The University of Chicago Chicago, Illinois 60637  <i>E-Mail:</i> msokolof@surgery.bsd.uchicago.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> This protocol is designed to evaluate the effects of combined anti-angiogenesis and androgen ablation therapy in men at high risk for recurrence after radical prostatectomy. Both clinical (pathologic, disease-free-survival, safety) and molecular factors will be evaluated. A clinical trial to test the effectiveness of this therapy was initiated in January 2003. After a slow initial accrual, recruitment has been increasing steadily. It is still too early to evaluate the anti-cancer efficacy of combined androgen ablation and anti-angiogenesis therapy, however, the drug has been well-tolerated and there have been no surgically-related complications. As more men are enrolled and undergo treatment, we will be able to evaluate the effects of this therapy on the natural history of prostate cancer.				
<b>14. SUBJECT TERMS</b> Experimental therapeutics; surgical therapy; anti-angiogenesis therapy			<b>15. NUMBER OF PAGES</b> 7	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>6</b>
<b>Reportable Outcomes.....</b>	<b>6</b>
<b>Conclusions.....</b>	<b>7</b>
<b>References.....</b>	<b>7</b>
<b>Appendices.....</b>	<b>7</b>

## ANNUAL REPORT

### “Combined Neoadjuvant Anti-angiogenesis & Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy” (DAMD17-02-1-0231)

August 29, 2003

## INTRODUCTION

High risk localized prostate cancer (preoperative PSA >10ng/ml, >50% Gleason grade 4 (or higher) on biopsy, and bilaterally bulky palpable disease) remains inadequately treated. While surgery and radiotherapy remain the treatments of choice, many men will fail despite these curative attempts. The role of neoadjuvant systemic chemotherapy has been proposed as a means of improving disease-free survival. We have successfully used a combination of castration and squalamine, a novel anti-angiogenic agent, to eradicate tumors in a preclinical model of human prostate cancer.

In this investigator-initiated phase II clinical trial application, we proposed to extend these findings to the clinical setting. Our principal goal is to assess whether combined androgen ablation and anti-angiogenesis therapy can improve outcomes for men with poor prognostic prostate cancer undergoing radical prostatectomy. The primary objectives of this proposal are to investigate if the combination of these agents results in pathologic downstaging and downgrading of the primary tumor, if tumor recurrence can be diminished, and whether anti-angiogenic agents can be given safely in the perioperative setting. The Specific Aims are outlined in the accompanying box.

#### Specific Aims

1. Specific Aim 1: To test the hypothesis that combined androgen ablation and anti-angiogenesis therapy will eradicate human prostate cancer.
2. Specific Aim 2: To test the hypothesis that androgen ablation therapy renders prostate tissue more susceptible to squalamine activity by inducing changes in VEGF/VEGF-receptor and integrin expression.
3. Specific Aim 3: To test the hypothesis that neoadjuvant combined androgen ablation and anti-angiogenesis therapy will diminish post-prostatectomy disease recurrence.

The primary objectives of this proposal are to investigate if the combination of these agents results in pathologic downstaging and downgrading of the primary tumor, if tumor recurrence can be diminished, and whether anti-angiogenic agents can be given safely in the perioperative setting. The Specific Aims are outlined in the accompanying box.

## BODY

To test our we hypothesize that disruption of stromal-epithelial interactions by androgen ablation renders both prostate epithelial and stromal endothelial cells more susceptible to anti-angiogenic drug activity through changes in VEGF, VEGF receptor, and integrin expression, we designed a phase II clinical trial. A schematic of the trial design is included as [Figure 1](#).




Figure 1: Schematic of clinical trial design

Preoperatively, patients will receive either androgen ablation therapy alone or combined androgen ablation and anti-angiogenesis therapy for six weeks. All patients will receive six weeks of combination androgen ablation and anti-angiogenesis therapy post-prostatectomy and will be followed prospectively for clinical evidence of disease recurrence. This randomized phase II clinical trial will investigate whether neoadjuvant combined androgen ablation and squalamine therapy is tolerable, feasible, and results in prolonged disease-free survival and pathologic downstaging and downgrading of established prostate cancers. Prostatectomy specimens will also be analyzed for changes in apoptosis, microvessel density, and VEGF, flt-1 receptor and integrin  $\alpha_V\beta_3$ ,  $\alpha_V\beta_5$  and  $\alpha_6\beta_4$  expression.

This proposed clinical trial targets a population of men who are at high risk for treatment failure yet for whom there are few available therapies other than conventional surgery or radiotherapy. We will attempt to establish a role for systemic therapy for these patients, evaluate the efficacy of anti-angiogenesis therapy in prostate cancer, and validate our putative mechanisms of action which suggest that for maximum benefit, anti-angiogenesis therapy should be given in combination with androgen ablation therapy. The **Statement of Work** is summarized in the accompanying box.

**STATEMENT OF WORK**

*Specific Aim 1: A randomized phase II clinical trial will investigate whether neoadjuvant combined androgen ablation and squalamine therapy is tolerated, feasible, and results in pathologic down-staging and downgrading of established prostate cancers.*

- ❖ Task 1: Identification and enrollment of one hundred and thirty-two men with prostate cancer with characteristics denoting a "high risk" for recurrence (months 0-30)
- ❖ Task 2: Treatment of the enrolled men with either neoadjuvant androgen ablation therapy or combined neoadjuvant androgen ablation and anti-angiogenesis therapy (months 0-32)
- ❖ Task 3: Completion of radical prostatectomies on all one hundred and thirty-two men (months 2-34)
- ❖ Task 4: Evaluation of prostatectomy specimens for evidence of down-staging and downgrading (months 2-34)
- ❖ Task 5: Evaluation of safety of radical prostatectomy after treatment with an anti-angiogenic agent (months 2-36)

*Specific Aim 2: To test the hypothesis that androgen ablation therapy renders prostate tissue more susceptible to squalamine activity by inducing changes in VEGF/VEGF-receptor and integrin expression.*

- ❖ Task 6: Evaluation of prostatectomy specimens and pre-prostatectomy prostate needle biopsies for changes in apoptosis, microvessel density, and VEGF, flt-1 receptor and integrin  $\alpha_V\beta_3$ ,  $\alpha_V\beta_5$  and  $\alpha_6\beta_4$  expression (months 2-36)
- ❖ Task 7: Comparison between androgen ablation alone and androgen ablation plus anti-angiogenesis treatment groups and between pretreatment (prostate needle biopsy) and post-treatment (radical prostatectomy) specimens (months 2-36)

*Specific Aim 3: In an extension study, all patients will receive eight weeks of combination therapy post-prostatectomy and will be followed prospectively for clinical evidence of disease recurrence.*

1. Task 8: Treatment of all enrolled men with adjuvant combined neoadjuvant androgen ablation and anti-angiogenesis therapy (months 2-36)
2. Task 9: Follow men prospectively for evidence of biochemical recurrence (months 2-36, and then through standard follow-up until month 72)

**Timetable**

Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
First 44 patients Neoadjuvant/Adjuvant Therapy Extension Study/Follow-up (average 2.5 years) Correlative Studies					
	Second 44 patients Neoadjuvant/Adjuvant Therapy Extension Study/Follow-up (average 2.5 years) Correlative Studies				
		Third 44 patients Neoadjuvant/Adjuvant Therapy Extension Study/Follow-up (average 2.5 years)			

Progress to Date

The trial official opened in January, 2003 with the first patient enrolled just six months ago (mid-February). To date, we have screened approximately 50 patients. Recruitment and accrual was slow at first. This has increased dramatically and we are now seeing at least four eligible patients weekly. To date, we have enrolled 7 men and have four others who intend to enroll once their staging studies and prostate biopsies are reviewed: we anticipate that all will qualify. Hence, including these additional patients, our accrual rate is at 50% of projected.

Of those patients screened who did not receive neoadjuvant therapy, the most common reason for not enrolling in the study included aversions to clinical trials, preference for non-surgical therapy, and ineligibility based on review of pathology.

To improve accrual, we have begun an outreach program in which community urologists and oncologists are educated on the clinical trial and encouraged to refer patients for consideration. We are also considering advertisements through the local media as part of our institutional publicity campaigns. We have seen a steady and progressive increase in interested patients and have little doubt that we will meet recruitment goals within the three years of enrollment (which will conclude in December 2005).

Only two patients treated with neoadjuvant therapy have completed their surgical treatment. Therefore, we do not yet have sufficient data to make any conclusions as to the effects of neoadjuvant combination therapy on pathologic downstaging and downgrading and changes in apoptosis, microvessel density, and VEGF, flt-1 receptor and integrin  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$  and  $\alpha_6\beta_4$  expression. This data will expand and mature in the coming months and we foresee having sufficient data for presentation at the national urology and cancer research meetings next Spring. Obviously, it is too premature to evaluate disease-free progression in these two men.

Surgery has been completed safely and successfully in all men treated under the protocol and there have been no surgically-related adverse events attributable to the experimental agent. As expected, there have been standard responses to the androgen ablation therapy (hot flashes, decreased libido and sexual function, lethargy), all of which have reverse after the hormonal ablation therapy was completed. There have also been several instances of discomfort at the injection site. Nevertheless, the drug has been tolerated well and there have been no major safety concerns, to date.

#### KEY RESEARCH ACCOMPLISHMENTS

As the first patient was enrolled only 6 months ago and as only two patients have been thus far treated with neoadjuvant therapy, we do not yet have sufficient data to make any conclusions as to its effects on pathologic downstaging and downgrading and changes molecular factors. Likewise, it is too premature to evaluate disease-free progression. Surgery has been completed safely and successfully in all men treated under the protocol and there have been no surgically-related adverse events attributable to the experimental agent.

We have been able to refine and expand our administrative infrastructure and our recruitment methods. Although we are only at 50% of projected enrollment, this was the result of a slow start. We have seen a steady and progressive increase in interested patients and have little doubt that we will meet recruitment goals within the three years of enrollment (which will conclude in December 2005).

#### REPORTABLE OUTCOMES

As the first patient was enrolled only 6 months ago and as only two patients have been thus far treated with neoadjuvant therapy, we do not yet have sufficient data to make any conclusions as to its effects on pathologic downstaging and downgrading and changes molecular factors. Likewise, it is too premature to evaluate disease-free progression. We anticipate acquiring sufficient data for presentation at the national urology and cancer research meetings next Spring.

## CONCLUSIONS

This proposed clinical trial targets a population of men who are at high risk for treatment failure yet for whom there are few available therapies other than conventional surgery or radiotherapy. After a delay in initiation and a slow start on accrual, our enrollment numbers are increasing and we are confident that we will meet all of our accruals. We believe that we will be able to establish a role for systemic therapy in "high risk" prostate cancer patients, conclusively evaluate the efficacy of anti-angiogenesis therapy in prostate cancer, and validate our putative mechanisms of action which suggest that for maximum benefit, anti-angiogenesis therapy should be given in combination with androgen ablation therapy.

## REFERENCES

None.

## APPENDICES

None.